Preterm birth and its complications are the leading cause of neonatal death. The main underlying pathological mechanisms for preterm complications are disruption of the normal maturation processes within the target tissues, interrupted by premature birth.
pathological mechanisms for preterm complications are disruptions of normal organ maturation, which is partly caused by target tissue stem cell depletion and damage from oxygen toxicity, infection/inflammation, and so on. [3] [4] [5] The brain and lungs are two organs commonly affected, the potential pathophysiology of which is neuron demyelination and alveolar dysmorphia, respectively. 4, 5 With the improvement of intensive care intervention, mortality rates of preterm babies decreased. However, many survivors still face a lifetime of disability, including long-term respiratory complications, learning disabilities, and visual and hearing problems, even in developed countries. 2 Current treatment strategies are single-organ targeted, and could not address the underlying multi-organ structural simplification.
Cord blood mononuclear cells layer is rich in valuable stem and progenitor cells (SPC). [4] [5] [6] On the one hand, they are capable of self-renewal; on the other hand, they have the potential to differentiate into various cellular phenotypes. 5 In addition, their paracrine effect contributes to tissue repair and immune modulation. 7, 8 Animal studies have demonstrated the effect of cord blood stem cells infusion in prevention and treatment of preterm-related complications such as bronchopulmonary dysplasia (BPD), sepsis, and hypoxic ischemic encephalopathy (HIE). 9, 10 Evidence from several clinical trials proved the safety and feasibility of autologous cord blood infusion in neonates. 4, [11] [12] [13] [14] [15] However, there are very limited data about preterm neonates. This led us to hypothesize that intravenous (IV) infusion of autologous cord blood mononuclear cells (ACBMNC) would lower the risk of developing preterm complications. The safety and feasibility of ACBMNC infusion in preterm infants has been demonstrated in our previous study. 4 In this prospective study, we analyzed whether ACBMNC could reduce preterm complications.
| MATERIALS AND METHODS

| Study design
This study included 31 preterm neonates less than 35 weeks gestational age (GA). Between 1 December 2009 and 1 July 2010, we conducted a single-center, phase II, prospective, nonrandomized, placebo-controlled trial of a single IV ACBMNC infusion in preterm infants less than 35 
| Participants and methods
Inborn infants admitted to the Neonatal Intensive Care Unit of Guangdong Women and Children Hospital were eligible if they were: (a) born in the study hospital, (b) singleton birth, (c) less than 35 weeks GA, (d) without congenital abnormalities (through prenatal screening), (e) without clinical chorioamnionitis, and (f) the mother was negative for hepatitis B (HBsAg and/or HBeAg) and C virus (anti-HCV), syphilis, HIV (anti-HIV-1 and -2) and IgM against cytomegalovirus, rubella, toxoplasma, and herpes simplex virus. If the neonates fulfilled the above criteria, we would talk with their parents before the delivery. If the consent for IV ACBMNC infusion was obtained from their parents or guardians, the cord blood would be collected. And the infants will be assigned to the ACBMNC infusion group if their umbilical cord blood (UCB) cells after processing were available. If the consent for IV ACBMNC infusion was not obtained, the cord blood would not be collected for this trial, and the parents could choose to deal with the cord blood as they preferred. These infants were assigned to the control group if their parents or guardians consented. Those assigned to the ACBMNC group received an infusion of ACBMNC with in 8 hours after birth. Those in the control group received an infusion of a placebo solution, which is normal saline of the same volume. Cell dose for all patients was targeted at 5 × 10 7 cells per kilogram.
| Procedures
Right before the preterm infant was delivered, written consent was signed by the parents. The procedure of cord blood collection was performed in accordance with cord blood bank guidance which was reported previously. 4 Guangdong Cord Blood and Stem Cell Bank is a public provincial blood bank affiliated to the Guangdong Women and Children's Hospital, which collects cord blood according to the consents in this hospital. Therefore, the cord blood of the neonates with consents had been routinely collected during the delivery. The procedure of cord blood collection and transfusion was performed in accordance with cord blood bank guidance. 16 The umbilical cord was clamped for the collection using a blood-collection bag (WEGO, China) containing 28 mL of citrate-phosphate-dextrose anticoagulant right after the baby was born and before the placenta was delivered. The umbilical vein was sterilized and punctured with a 17-gauge needle. UCB collection was made by
Significance statement
The results from this prospective nonrandomized study found that autologous cord blood cells infusion substantially reduced the duration of mechanical ventilation and oxygen supplement. Fewer preterm complications were observed in the cord blood cell infusion group, although there was no significant difference. Preterm birth complications are the first major direct cause of neonatal death, and no curative therapies are available to alleviate the symptoms of preterm complications. Stem cells as a treatment provides regrowth to their underdeveloped organs and therefore could improve the outcomes of preterm infants by adding more stem/progenitor cells. This may be helpful to prevent preterm complications.
trained obstetricians or cord blood bank collection staff who were present at hospital during weekdays for 8-12 hours per day. When collection was completed, the blood bag tubing was closed and sealed. Cord blood labeled with full name of donor, group type, and volume of the blood product was stored in 4 C and sent to the Cord Blood and Stem Cell Bank for processing immediately. Before processing, 2 mL of samples were taken from all collected CB units to test for the presence of virus (human immunodeficiency virus, hepatitis B virus, hepatitis C virus, cytomegalovirus) and bacterial infections (Treponema pallidum included).
A sample of peripheral blood was collected from the mother and tested for the presence of maternal transmissible diseases. And the results were obtained soon before transfusion started. After the sample was taken, it was volume and red blood cell (RBC) was reduced after Chest radiographs were performed at admission and 8 hours after ACBMNC infusion on the first day of life in all surviving patients. Blood gas was monitored at least every 24 hours until weaning from ventilation. All clinical diagnoses were defined according to a standard reference. 17 Assessment of safety were conducted at 12 and 24 hours after infusion, as well as during hospitalization and return visits. Laboratory investigations in peripheral blood were monitored and kept stable during the whole treatment period. Infusion reactions and signs of circulatory overload were checked. A hospital ethics committee reviewed the study data during the trial. None of them were involved in the study.
The staff who collected and analyzed the patients data were not aware of the treatment assignment.
| Outcomes
The primary outcome of this study is the mortality rate before discharge. The secondary outcomes are preterm complications rate before discharge. Other outcomes included duration of mechanical ventilation and oxygen therapy, reintubation, and time of return to BW. Preterm complications included BPD, intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), retinopathy of prematurity (ROP), respiratory distress syndrome (RDS), ventilationassociated pneumonia (VAP), HIE, late onset sepsis (LOS), and anemia. All clinical diagnoses were defined according to a standard reference. 17 
| Statistical analysis
Statistical analyses between the two groups were performed using an unpaired two-tailed Student's t test or Chi-squared test as appropriate. A value of P < .05 was considered statistically significant. All statistical analyses were done using SPSS 21.0 (IBM).
| RESULTS
| Study infants and intervention
A total of 31 infants were enrolled between 1 December 2009 and 1 July 2010 in our single center. All patients were followed up to their first discharge home. There were no significant differences in the baseline characteristics and status of the infants in the two groups ( Table 1 ).
| Study intervention
The characteristics of the ACBMNC and the use of PS or oxygen in the two groups are shown in Tables 2 and 3 . Study infants received the ACBMNC at a median hours after birth of 6.77 ± 1.52 hours, and 
| Outcomes
| Primary outcome (mortality)
All infants survived to discharge in both groups (Table 3 ).
| Secondary outcome
The secondary outcomes and other outcomes in the two groups before discharge are shown in ACBMNC infusion group. The rates of anemia, VAP, and RDS grade more than 2 did not differ significantly between the two groups.
Duration of Hospitalization was similar in both groups.
During the first 24 hours, infants in the ACBMNC infusion group had more white blood cells (WBC) than infants in the placebo group (Table 4 ). No significant differences in hemoglobin (HB), platelet (PLT), and blood gas after 24 hours were observed.
| DISCUSSION
In this prospective nonrandomized study, we analyzed whether ACBMNC infusion soon after birth could reduce preterm complications in preterm neonates. This article focuses on short-term outcomes before discharge. We found no infants were dead before T A B L E 2 Characteristics of the ACBMNC Preterm complications continue to be a significant cause of morbidity and mortality for premature infants. 2 The underlying pathological mechanisms for preterm complications are disruptions of normal organ maturation. 3 The brain and lung are two organs commonly affected, clinical presented as HIE and BPD, respectively. 3, 5, 9, [18] [19] [20] [21] [22] [23] [24] Until now, the treatments for these complications are single-organ or symptom targeted. 22, 23 We are looking for a therapy that has the potential to cope with these multiple factors.
Previous study reported the sudden lack of circulating cord blood at the time of preterm birth results in a lack of progenitor cells for normal tissue maturation. 9, 21 However, recent study showed the disruption of the normal maturation processes within the target tissues, interrupted by premature birth, which is partially responsible for abnormal end organ development. 3 Stem cells have the potential to give rise to multiple differentiated cellular phenotypes. However, later research showed stem cells engraftment seems to be a rare event, 3, 22, 23 stem cells as a treatment probably does not provide regrowth of underdeveloped organs directly. 7, 12 Growing number of studies have shown that stem cells interact with injured tissue through the release of soluble bioactive factors, which have immunomodulatory and anti-inflammatory effects. 3, 4, 7, 9, 25 This evidence laid the foundation for MNCs as a new systemic, multi-organ targeted therapy for preterm complication prevention.
BPD is considered as one of the major complications of preterm birth. 3, 4 The new definition of BPD addressed that it is a chronic lung disease associated with an arrest in lung development including alveolar and vascular structural development. Despite the rapid advance of neonatal care, BPD remains a significant burden for the preterm population, which is lack of effective intervention. 3, 4 Ahn and the colleagues had demonstrated that intratracheal transplantation of allogeneic hUCB-derived mesenchymal stem cells (MSCs) is safe, feasible, and effective in preterm infants at high risk for BPD. 11, 13 Matthay and team showed that IV allogeneic BM-MSCs was safe in adults with ARDS. 26 Compared with other stem cell types in cord blood, MSCs are more attractive to researchers, as it is nonimmunogenic and can be expanded rapidly ex vivo. 7, 27 With these properties, allogeneic transplantation of MSCs are used for treatment of diseases in adult and neonates. 11, 26, 28 ACBMNC, as a convenient source of MSC, has never been studied in prevention or treatment of BPD in preterm. Valuable SPC mainly exits in MNC layer. 12, 27 It is Note: Bold entries denote, during the first 24 hours, infants in the ACBMNC infusion group had more white blood cells (WBC) than infants in the placebo group (P = .042). Infants in the ACBMNC infusion group had more platelets before infusion (P = .002).
source including cord blood MNC vs MSCs are warranted. Oxygenand mechanical ventilation-mediated lung injury have been implicated in the pathogenesis of BPD. 5, 32 In the management of BPD, mechanical ventilation is the main method to maintain lung volume in preterm, however, all methods of ventilation can damage the epithelium and increase inflammation response. In addition, even oxygen supplementation at low levels can cause oxidative stress and damage the development of the immature lung. 32, 33 Our study is the first research observing the effect of ACBMNC as a potential treatment option for BPD. We found no one had BPD in 15 infants receiving ACBMNC infusion; furthermore, ACBMNC infusion reduced mechanical ventilation and oxygen supplement duration obviously, and therefore could shorten exposure to oxygen and attenuate lung injury associated with oxidative stress. However, more research regarding the underlying mechanisms are needed.
Preterm infants are vulnerable to brain injury, including HIE and IVH. HIE and IVH can lead to cerebral palsy (CP) causing functional impairments and lifelong disabilities. 12, 19, [33] [34] [35] [36] [37] SPC in cord blood obtained several advantages over the use of other SPC source, including immunomodulatory capacity, anti-fibrosis activity, antiapoptotic activity, endogenous repair, and growth promoting activity. 9, 27 Recently, both autologous and allogeneic cord blood infusion are applied in the treatment of HIE, IVH, and CP. 12, 15, 35 Cotten and colleagues in Duke University tested feasibility and safety of providing autologous UCB cells to neonates ≥35 weeks with HIE and found that UCB cells infusion could improve neurodevelopmental outcomes after 1-year follow-up. 12 Kotowski transfused whole cord blood in preterm neonates to treat anemia and compared IVH rate in infants infused RBCs, and found lower IVH rate in cord blood infusion group. 15 Kurtzberg demonstrated that appropriately dosed ACB infusion improves motor function in young children with CP, 36 and they suggested improvements in motor function resulted from new brain connectivity induced by paracrine signaling of ACB cells. In a recent research, Wasielewski and the colleagues found inflammatory activation decreased after UCB cells treatment in an HIE rat model. 38 They and other researchers also showed that UCB cells could improve secretion of vascular endothelial growth factor, reduce apoptosis, and accelerate angiogenesis post brain injury. [38] [39] [40] These previous studies suggested that cord blood stem cell therapy has beneficial effect on premature brain injury. Compared with nearterm neonates and older children, very preterm infants, with immature blood brain barrier and simpler cerebral structure, are more prone to brain damage related to fluctuations in cerebral oxygenation. 34, 37 Preterm infants often require mechanical or assisted ventilation after birth. This can cause brain injury through oxidative stress. 37 Preoligodendrocytes are highly vulnerable to oxidative stress. 9 We infused ACBMNC in very preterm neonates, and found beneficial effect on reducing duration of mechanical ventilation and oxygen usage, which may protect brain tissue via attenuating oxidative stress. However, the underlying cellular mechanisms on how UCB cells improve neurodevelopment are complex. More research on our mechanistic understanding of paracrine and non paracrine pathways for UCB cells therapy should be conducted. 41, 42 Rare studies evaluated the stem cell therapy effect on other common complications such as LOS, RDS, NEC, and ROP, which resulted from immaturity of immune system, pulmonary, intestine, and retina, respectively. Although the immunomodulatory and therapeutic effects of stem cells for the lung injury and sepsis were reported in adults, 7 no exact data were reported about the special population of neonates.
Our study first reported the concrete number of patients diagnosed with various complications in ACBMNC infusion and control group.
No significant difference was found which may be due to the limited number of participants. Regarding the incidence of ROP, the study group was not with high risk of this complication development since there were no babies below 29 GA, and since the complication may develop later than 30 days after the birth, the longer observation is required to definitely exclude ROP incidence.
For the laboratory tests, during the first 24 hours, infants in the ACBMNC infusion group had more WBC than infants in the placebo group, which may be partly attributed to the infusion of MNCs from cord blood compared with no cells in normal saline infused in control group. Other mechanisms including immunoregulation may also play a role; however, more research is needed to understand the underlying reasons.
To our knowledge, this is the first study to assess ACBMNC transfusion very soon after birth in very preterm neonates in relation to the rate of prematurity-related complications. We reported here for the first time that ACBMNC infusion soon after birth was safe and feasible, and demonstrated significantly great decreases in duration of mechanical ventilation and oxygen therapy. No BPD, NEC, ROP, and HIE were observed in ACBMNC infusion group, indicating that ACBMNC may have the potential to reduce the rate of prematurity complications.
This study certainly has some limitations. First, the sample size is small and the study group does not involve substantial number of immature babies (eg,~1000 g of birth weight). These characters could make the conclusion less accurate and may lead to loss of truth in significant difference regarding complication rate in two groups. Second, this study is nonrandomized and single-blind, and this may cause bias.
Considering these limitations, further multicenter, randomized, double-blinded, placebo controlled trials in more immature neonates are needed to prove the effectiveness. 43 
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